Key clinical point:
Major finding: At week 16 of the initial treatment period, Psoriasis Area and Severity Index (PASI)175 was reached by significantly more of the patients in the 0.8 mg/kg adalimumab group (22 of 38 [58%]) than in the methotrexate group (12 of 37 [32%]).
Data source: A double-blind, phase III trial was done at 38 clinics in 13 countries with 114 children aged 4-17 years, with severe plaque psoriasis that had not responded to topical therapy.
Disclosures: The study was funded by AbbVie. Dr. Papp has served as a consultant for adalimumab manufacturer AbbVie and a number of other pharmaceutical companies for which he has served as consultant or speaker or on advisory boards. His associates listed numerous similar disclosures. Two authors were AbbVie employees.Full Article